Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Characterising variability and regional correlations of microstructure and mechanical competence of human tibial trabecular bone: An in-vivo HR-pQCT study.

Du J, Brooke-Wavell K, Paggiosi MA, Hartley C, Walsh JS, Silberschmidt VV, Li S.

Bone. 2019 Apr;121:139-148. doi: 10.1016/j.bone.2019.01.013. Epub 2019 Jan 15.

PMID:
30658093
2.

Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.

Naylor KE, McCloskey EV, Jacques RM, Peel NFA, Paggiosi MA, Gossiel F, Walsh JS, Eastell R.

Osteoporos Int. 2019 Apr;30(4):917-922. doi: 10.1007/s00198-018-04823-5. Epub 2019 Jan 6.

PMID:
30613868
3.

Effect of vitamin D supplementation on free and total vitamin D: A comparison of Asians and Caucasians.

Gopal-Kothandapani JS, Evans LF, Walsh JS, Gossiel F, Rigby AS, Eastell R, Bishop NJ.

Clin Endocrinol (Oxf). 2019 Jan;90(1):222-231. doi: 10.1111/cen.13825. Epub 2018 Sep 9.

4.

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.

Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.

Osteoporos Int. 2018 Jun;29(6):1407-1417. doi: 10.1007/s00198-018-4460-6. Epub 2018 Mar 10.

5.

Bone: Microarchitecture of bone predicts fractures in older women.

Eastell R, Walsh JS.

Nat Rev Endocrinol. 2018 May;14(5):255-256. doi: 10.1038/nrendo.2018.27. Epub 2018 Mar 9. No abstract available.

6.

Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.

Paggiosi MA, Yang L, Blackwell D, Walsh JS, McCloskey E, Peel N, Eastell R.

Osteoporos Int. 2018 Jun;29(6):1367-1378. doi: 10.1007/s00198-018-4445-5. Epub 2018 Mar 8.

7.

Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.

Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1302-1309. doi: 10.1210/jc.2017-00283.

8.

Anabolic treatment for osteoporosis: teriparatide.

Eastell R, Walsh JS.

Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):173-178. doi: 10.11138/ccmbm/2017.14.1.173. Epub 2017 Oct 25. Review.

9.

DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?

Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA.

Eur J Endocrinol. 2018 Jan;178(1):R19-R31. doi: 10.1530/EJE-17-0585. Epub 2017 Oct 18. Review.

10.

Vitamin D in obesity.

Walsh JS, Bowles S, Evans AL.

Curr Opin Endocrinol Diabetes Obes. 2017 Dec;24(6):389-394. doi: 10.1097/MED.0000000000000371. Review.

11.

Effect of age and gender on serum periostin: Relationship to cortical measures, bone turnover and hormones.

Walsh JS, Gossiel F, Scott JR, Paggiosi MA, Eastell R.

Bone. 2017 Jun;99:8-13. doi: 10.1016/j.bone.2017.03.041. Epub 2017 Mar 16.

12.

Obesity, Type 2 Diabetes and Bone in Adults.

Walsh JS, Vilaca T.

Calcif Tissue Int. 2017 May;100(5):528-535. doi: 10.1007/s00223-016-0229-0. Epub 2017 Mar 9. Review.

13.

Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health.

Walsh JS, Evans AL, Bowles S, Naylor KE, Jones KS, Schoenmakers I, Jacques RM, Eastell R.

Am J Clin Nutr. 2016 Jun;103(6):1465-71. doi: 10.3945/ajcn.115.120139. Epub 2016 May 11.

PMID:
27169839
14.

Bone turnover markers: response to comments by Seeman and Nguyen.

Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.

Osteoporos Int. 2016 Jan;27(1):37. doi: 10.1007/s00198-015-3389-2. Epub 2015 Nov 11. No abstract available.

15.

Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study.

Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM, Han TS.

Clin Endocrinol (Oxf). 2016 Feb;84(2):296-304. doi: 10.1111/cen.12869. Epub 2015 Sep 1.

PMID:
26248973
16.

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.

Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.

Osteoporos Int. 2016 Jan;27(1):21-31. doi: 10.1007/s00198-015-3145-7. Epub 2015 May 20.

17.

Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood.

Evans AL, Paggiosi MA, Eastell R, Walsh JS.

J Bone Miner Res. 2015 May;30(5):920-8. doi: 10.1002/jbmr.2407.

18.

Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.

Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.

Osteoporos Int. 2014 Dec;25(12):2729-41. doi: 10.1007/s00198-014-2817-z. Epub 2014 Jul 30.

PMID:
25074351
19.

Osteogenesis imperfecta in adults.

Bishop NJ, Walsh JS.

J Clin Invest. 2014 Feb;124(2):476-7. doi: 10.1172/JCI74230. Epub 2014 Jan 27.

20.

Precision of high-resolution peripheral quantitative computed tomography measurement variables: influence of gender, examination site, and age.

Paggiosi MA, Eastell R, Walsh JS.

Calcif Tissue Int. 2014 Feb;94(2):191-201. doi: 10.1007/s00223-013-9798-3. Epub 2013 Sep 22.

PMID:
24057069
21.

Osteoporosis in men.

Walsh JS, Eastell R.

Nat Rev Endocrinol. 2013 Nov;9(11):637-45. doi: 10.1038/nrendo.2013.171. Epub 2013 Sep 10. Review.

PMID:
24019112
22.

Is it time to combine osteoporosis therapies?

Eastell R, Walsh JS.

Lancet. 2013 Jul 6;382(9886):5-7. doi: 10.1016/S0140-6736(13)60984-8. Epub 2013 May 15. No abstract available.

PMID:
23683601
23.

Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome.

Walsh JS, Newell-Price JD, DeBono M, Adaway J, Keevil B, Eastell R.

J Clin Endocrinol Metab. 2013 Jul;98(7):2902-7. doi: 10.1210/jc.2012-4174. Epub 2013 Apr 30.

24.

Role of estrogen in the age-related decline in bone microstructure.

Walsh JS, Eastell R.

J Clin Endocrinol Metab. 2013 Feb;98(2):519-21. doi: 10.1210/jc.2013-1049. No abstract available.

PMID:
23390264
25.

Cortical consolidation of the radius and tibia in young men and women.

Walsh JS, Paggiosi MA, Eastell R.

J Clin Endocrinol Metab. 2012 Sep;97(9):3342-8. doi: 10.1210/jc.2012-1677. Epub 2012 Jul 3.

PMID:
22761460
26.

Neutrophilic dermatosis caused by azathioprine.

Valentine MC, Walsh JS.

Skinmed. 2011 Nov-Dec;9(6):386-8. No abstract available.

PMID:
22256629
27.

Heart drugs that affect bone.

Walsh JS, Newman C, Eastell R.

Trends Endocrinol Metab. 2012 Apr;23(4):163-8. doi: 10.1016/j.tem.2011.10.002. Epub 2011 Dec 1. Review.

PMID:
22136934
28.

Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis.

Brewer JD, Christenson LJ, Weaver AL, Dapprich DC, Weenig RH, Lim KK, Walsh JS, Otley CC, Cherikh W, Buell JF, Woodle ES, Arpey C, Patton PR.

Arch Dermatol. 2011 Jul;147(7):790-6. doi: 10.1001/archdermatol.2011.159.

PMID:
21768478
29.

Very low birth weight survivors have reduced peak bone mass and reduced insulin sensitivity.

Smith CM, Wright NP, Wales JK, Mackenzie C, Primhak RA, Eastell R, Walsh JS.

Clin Endocrinol (Oxf). 2011 Oct;75(4):443-9. doi: 10.1111/j.1365-2265.2011.04118.x.

PMID:
21635277
30.

Obesity is a risk factor for fracture in children but is protective against fracture in adults: a paradox.

Dimitri P, Bishop N, Walsh JS, Eastell R.

Bone. 2012 Feb;50(2):457-66. doi: 10.1016/j.bone.2011.05.011. Epub 2011 May 18. Review.

PMID:
21619952
31.

Bisphosphonates for postmenopausal osteoporosis.

Eastell R, Walsh JS, Watts NB, Siris E.

Bone. 2011 Jul;49(1):82-8. doi: 10.1016/j.bone.2011.02.011. Epub 2011 Feb 22. Review.

PMID:
21349354
32.

Bioactivation of drugs: risk and drug design.

Walsh JS, Miwa GT.

Annu Rev Pharmacol Toxicol. 2011;51:145-67. doi: 10.1146/annurev-pharmtox-010510-100514. Review.

PMID:
21210745
33.

Feeding and bone.

Walsh JS, Henriksen DB.

Arch Biochem Biophys. 2010 Nov 1;503(1):11-9. doi: 10.1016/j.abb.2010.06.020. Epub 2010 Jun 23. Review.

PMID:
20599659
34.

Bone: causes of low bone mass in breast cancer-time for action?

Coleman RE, Walsh JS.

Nat Rev Endocrinol. 2010 Jan;6(1):10-2. doi: 10.1038/nrendo.2009.244. No abstract available.

PMID:
20010963
35.

Hormonal determinants of bone turnover before and after attainment of peak bone mass.

Walsh JS, Henry YM, Fatayerji D, Eastell R.

Clin Endocrinol (Oxf). 2010 Mar;72(3):320-7. doi: 10.1111/j.1365-2265.2009.03606.x. Epub 2009 Apr 17.

PMID:
19508592
36.

Drug-induced liver injury following positive drug rechallenge.

Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM.

Regul Toxicol Pharmacol. 2009 Jun;54(1):84-90. doi: 10.1016/j.yrtph.2009.03.003. Epub 2009 Mar 18.

PMID:
19303041
37.

Cutaneous ganglioneuroma associated with overlying hyperkeratotic epidermal changes: a report of 2 cases.

Furmanczyk PS, Hughes SR, Walsh JS, Bass J, McFarlane JR, Argenyi ZB.

Am J Dermatopathol. 2008 Dec;30(6):600-3. doi: 10.1097/DAD.0b013e3181834acd. Review.

PMID:
19033938
38.

Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density.

Walsh JS, Eastell R, Peel NF.

Fertil Steril. 2010 Feb;93(3):697-701. doi: 10.1016/j.fertnstert.2008.10.004. Epub 2008 Nov 14.

PMID:
19013564
39.

Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study.

Walsh JS, Henry YM, Fatayerji D, Eastell R.

Osteoporos Int. 2009 Mar;20(3):355-62. doi: 10.1007/s00198-008-0672-5. Epub 2008 Jul 16.

PMID:
18629566
40.

Outcomes of melanoma in recipients of solid organ transplant.

Dapprich DC, Weenig RH, Rohlinger AL, Weaver AL, Quan KK, Keeling JH, Walsh JS, Otley CC, Christenson LJ.

J Am Acad Dermatol. 2008 Sep;59(3):405-17. doi: 10.1016/j.jaad.2008.05.015. Epub 2008 Jun 16.

PMID:
18556089
41.

Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study.

Walsh JS, Eastell R, Peel NF.

J Clin Endocrinol Metab. 2008 Apr;93(4):1317-23. doi: 10.1210/jc.2007-2201. Epub 2008 Jan 29.

PMID:
18230659
42.

Prevalence and ethnicity of sleep-disordered breathing and obesity in children.

Rudnick EF, Walsh JS, Hampton MC, Mitchell RB.

Otolaryngol Head Neck Surg. 2007 Dec;137(6):878-82.

PMID:
18036414
43.

Cutaneous involvement with Burkitt-like lymphoma.

Pettey AA, Walsh JS.

Am J Dermatopathol. 2007 Apr;29(2):184-6.

PMID:
17414444
44.

Evaluation of a protocol for prevention of facility-acquired heel pressure ulcers.

Walsh JS, Plonczynski DJ.

J Wound Ostomy Continence Nurs. 2007 Mar-Apr;34(2):178-83.

PMID:
17413835
45.

Eruptive epidermoid cysts resulting from treatment with imiquimod.

Marty CL, Randle HW, Walsh JS.

Dermatol Surg. 2005 Jul;31(7 Pt 1):780-2; discussion 782-3.

PMID:
16029707
46.

Muir-Torre syndrome: a case report and review of the literature.

Pettey AA, Walsh JS.

Cutis. 2005 Mar;75(3):149-55. Review.

PMID:
15839358
47.

Subcutaneous nodules on the face--quiz case.

Andrews TR, Calamia KT, Waldorf JC, Walsh JS.

Arch Dermatol. 2005 Jan;141(1):93-8. No abstract available.

PMID:
15655152
48.

Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus: report of three cases and review of the literature.

Hall VC, Goyal S, Davis MD, Walsh JS.

Int J Dermatol. 2004 Sep;43(9):648-53. Review.

PMID:
15357743
49.

Treatment of multicentric reticulohistiocytosis with etanercept.

Kovach BT, Calamia KT, Walsh JS, Ginsburg WW.

Arch Dermatol. 2004 Aug;140(8):919-21. No abstract available.

PMID:
15313806
50.

Erythema multiforme associated with candesartan cilexetil.

Ejaz AA, Walsh JS, Wasiluk A.

South Med J. 2004 Jun;97(6):614-5.

PMID:
15255435

Supplemental Content

Loading ...
Support Center